 |
The Journal of Neuroscience, September 15, 2004, 24(37):8009-8018; doi:10.1523/JNEUROSCI.1508-04.2004
Previous Article | Next Article 
Behavioral/Systems/Cognitive
Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkA
Martin A. Bruno,1
Paul B. S. Clarke,1
Alicia Seltzer,6
Rémi Quirion,1,2
Kevin Burgess,7
A. Claudio Cuello,1,3 * and
H. Uri Saragovi1,4,5 *
Departments of 1Pharmacology and Therapeutics, 2Psychiatry/Douglas Hospital Research Center, 3Anatomy and Cell Biology, and 4Oncology/Cancer Center, and 5Lady Davis Research Institute, McGill University, Montréal, Quebec, H3T 1E2 Canada, 6Facultad de Medicina, Universidad de Cuyo, Mendoza 5500, Argentina, and 7Department of Chemistry, Texas A&M University, College Station, Texas 77842
Previously, we developed a proteolytically stable small molecule peptidomimetic termed D3 as a selective ligand of the extracellular domain of the TrkA receptor for the NGF. Ex vivo D3 was defined as a selective, partial TrkA agonist. Here, the in vivo efficacy of D3 as a potential therapeutic for cholinergic neurons was tested in cognitively impaired aged rats, and we compared the consequence of partial TrkA activation (D3) versus full TrkA/p75 activation (NGF). We show that in vivo D3 binds to TrkA receptors and affords a significant and long-lived phenotypic rescue of the cholinergic phenotype both in the cortex and in the nucleus basalis. The cholinergic rescue was selective and correlates with a significant improvement of memory/learning in cognitively impaired aged rats. The effects of the synthetic ligand D3 and the natural ligand NGF were comparable. Small, proteolytically stable ligands with selective agonistic activity at a growth factor receptor may have therapeutic potential for neurodegenerative disorders.
Key words: peptidomimetic; age; cognition; memory; TrkA; NGF; agonist; cholinergic; CNS
Received June 25, 2003;
revised July 29, 2004;
accepted August 3, 2004.
This article has been cited by other articles:

|
 |

|
 |
 
A. M. Colangelo, M. R. Bianco, L. Vitagliano, C. Cavaliere, G. Cirillo, L. De Gioia, D. Diana, D. Colombo, C. Redaelli, L. Zaccaro, et al.
A New Nerve Growth Factor-Mimetic Peptide Active on Neuropathic Pain in Rats
J. Neurosci.,
March 12, 2008;
28(11):
2698 - 2709.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Bruno and A. C. Cuello
Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade
PNAS,
April 25, 2006;
103(17):
6735 - 6740.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|